Dianthus Therapeutics, Inc. (DNTH)Healthcare | Biotechnology | New York, United States | NasdaqCM
105.84 USD
-5.70
(-5.110%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 115.40 +9.56 (9.033%) ⇧ (Aug. 28, 2026, 7:47 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:09 a.m. EDT
DNTH presents a classic biotech dichotomy: a fortress balance sheet with ample cash reserves and zero debt contrasts sharply with a seven-year price history of severe underperformance. The recent surge to near 52-week highs, driven by the initiation of a major Phase 3 clinical trial, has reignited institutional interest, evidenced by heavy buying from major asset managers. While the statistical forecasting models offer only a weak lean upward, the technical momentum remains robust with the stock trading well above its 200-day average. Investors should view this as a high-risk, high-reward speculative play where the downside is cushioned by the company's liquidity, but the path to profitability remains steep. The options market is hedging against a drop to the $70s while betting on a breakout toward $150, reflecting the binary nature of the upcoming trial results. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.094266 |
| MSTL | 0.124291 |
| AutoARIMA | 0.135528 |
| AutoETS | 0.135955 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 5.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.506 |
| Excess Kurtosis | -0.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.11 |
| Revenue per Share | 0.041 |
| Market Cap | 5,785,873,920 |
| Forward P/E | -22.31 |
| Beta | 0.08 |
| Website | https://dianthustx.com |
As of Aug. 22, 2026, 4:09 a.m. EDT: Speculators are positioning for a range-bound recovery with significant downside protection at the $65-$80 level via deep out-of-the-money puts, while call interest clusters at $150-$165, suggesting a potential upside target if the Phase 3 trial data validates expectations. Implied volatility is elevated on deep strikes, indicating uncertainty around binary outcomes.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.437736 |
| Address1 | 7 Times Square |
| Address2 | 43rd Floor |
| All Time High | 336.0 |
| All Time Low | 5.12 |
| Ask | 106.69 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 570,220 |
| Average Daily Volume3 Month | 1,046,374 |
| Average Volume | 1,046,374 |
| Average Volume10Days | 570,220 |
| Beta | 0.082 |
| Bid | 106.24 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 21.388 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 105.84 |
| Current Ratio | 26.1 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 111.31 |
| Day Low | 105.6 |
| Debt To Equity | 0.11 |
| Display Name | Dianthus Therapeutics |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -217,720,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -23.124 |
| Enterprise To Revenue | 2,644.206 |
| Enterprise Value | 5,034,568,704 |
| Eps Current Year | -3.92 |
| Eps Forward | -4.74333 |
| Eps Trailing Twelve Months | -4.24 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 103.3468 |
| Fifty Day Average Change | 2.4931946 |
| Fifty Day Average Change Percent | 0.024124546 |
| Fifty Two Week Change Percent | 343.7736 |
| Fifty Two Week High | 117.88 |
| Fifty Two Week High Change | -12.040001 |
| Fifty Two Week High Change Percent | -0.102137774 |
| Fifty Two Week Low | 23.39 |
| Fifty Two Week Low Change | 82.45 |
| Fifty Two Week Low Change Percent | 3.5250106 |
| Fifty Two Week Range | 23.39 - 117.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,587,800,000 |
| Float Shares | 55,849,917 |
| Forward Eps | -4.74333 |
| Forward P E | -22.313437 |
| Free Cashflow | -92,210,496 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 92 |
| Fullday Change | -5.7 |
| Fullday Change Percent | -5.11028 |
| Fullday Price | 115.4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 1.0 |
| Gross Profits | 1,904,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00124 |
| Held Percent Institutions | 1.28112 |
| Implied Shares Outstanding | 54,666,233 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. |
| Long Name | Dianthus Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 5,785,873,920 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_631649032 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -192,246,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,243,395,272 |
| Number Of Analyst Opinions | 13 |
| Open | 111.31 |
| Operating Cashflow | -155,375,008 |
| Operating Margins | -80.79106 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 929 999 4055 |
| Post Market Change | 9.560005 |
| Post Market Change Percent | 9.032507 |
| Post Market Price | 115.4 |
| Post Market Time | 1,787,960,875 |
| Previous Close | 111.54 |
| Price Eps Current Year | -26.999998 |
| Price Hint | 2 |
| Price To Book | 4.948569 |
| Price To Sales Trailing12 Months | 3,038.7993 |
| Profit Margins | 0.0 |
| Quick Ratio | 25.791 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -5.7 |
| Regular Market Change Percent | -5.11028 |
| Regular Market Day High | 111.31 |
| Regular Market Day Low | 105.6 |
| Regular Market Day Range | 105.6 - 111.31 |
| Regular Market Open | 111.31 |
| Regular Market Previous Close | 111.54 |
| Regular Market Price | 105.84 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 376,184 |
| Return On Assets | -0.1769 |
| Return On Equity | -0.26065 |
| Revenue Growth | 2.943 |
| Revenue Per Share | 0.041 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 54,666,233 |
| Shares Percent Shares Out | 0.1505 |
| Shares Short | 8,418,356 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 9,220,028 |
| Short Name | Dianthus Therapeutics, Inc. |
| Short Percent Of Float | 0.1727 |
| Short Ratio | 10.01 |
| Source Interval | 15 |
| State | NY |
| Symbol | DNTH |
| Target High Price | 200.0 |
| Target Low Price | 109.0 |
| Target Mean Price | 137.61539 |
| Target Median Price | 132.0 |
| Total Cash | 886,812,992 |
| Total Cash Per Share | 15.855 |
| Total Debt | 1,287,000 |
| Total Revenue | 1,904,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.24 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 74.27775 |
| Two Hundred Day Average Change | 31.562248 |
| Two Hundred Day Average Change Percent | 0.424922 |
| Type Disp | Equity |
| Volume | 376,184 |
| Website | https://dianthustx.com |
| Zip | 10,036 |